دورية أكاديمية
أعرض في EDS

Exploring antithrombin: insights into its physiological features, clinical implications and analytical techniques.

التفاصيل البيبلوغرافية
العنوان: Exploring antithrombin: insights into its physiological features, clinical implications and analytical techniques.
المؤلفون: Saboor M; Department of Medical Laboratory Sciences, College of Health Sciences, University of Sharjah, Sharjah, United Arab Emirates., Hamali HA; Department of Medical Laboratory Technology, College of Applied Medical Sciences, Jazan University, Jazan, Saudi Arabia., Mobarki AA; Department of Medical Laboratory Technology, College of Applied Medical Sciences, Jazan University, Jazan, Saudi Arabia., Madkhali AM; Department of Medical Laboratory Technology, College of Applied Medical Sciences, Jazan University, Jazan, Saudi Arabia., Dboie G; Department of Medical Laboratory Technology, College of Applied Medical Sciences, Jazan University, Jazan, Saudi Arabia.
المصدر: Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis [Blood Coagul Fibrinolysis] 2024 Mar 01; Vol. 35 (2), pp. 43-48. Date of Electronic Publication: 2023 Dec 15.
نوع المنشور: Review; Journal Article
اللغة: English
بيانات الدورية: Publisher: Lippincott Williams And Wilkins Country of Publication: England NLM ID: 9102551 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1473-5733 (Electronic) Linking ISSN: 09575235 NLM ISO Abbreviation: Blood Coagul Fibrinolysis Subsets: MEDLINE
أسماء مطبوعة: Publication: London : Lippincott Williams And Wilkins
Original Publication: Oxford, UK : Rapid Communications of Oxford Ltd., c1990-
مواضيع طبية MeSH: Antithrombins*/therapeutic use , Antithrombins*/chemistry , Antithrombin III Deficiency*/drug therapy, Humans ; Antithrombin III ; Anticoagulants ; Heparin ; Blood Coagulation
مستخلص: Antithrombin is an essential protein that acts as a natural anticoagulant in the human body. It is synthesized by the liver and belongs to the serine protease inhibitors, which are commonly referred to as the SERPINS superfamily. The antithrombin molecule comprises 432 amino acids and has a molecular weight of approximately 58 200 D. It consists of three domains, including an amino-terminal domain, a carbohydrate-rich domain, and a carboxyl-terminal domain. The amino-terminal domain binds with heparin, whereas the carboxyl-terminal domain binds with serine protease. Antithrombin is a crucial natural anticoagulant that contributes approximately 60-80% of plasma anticoagulant activities in the human body. Moreover, antithrombin has anti-inflammatory effects that can be divided into coagulation-dependent and coagulation-independent effects. Furthermore, it exhibits antitumor activity and possesses a broad range of antiviral properties. Inherited type I antithrombin deficiency is a quantitative disorder that is characterized by low antithrombin activity due to low plasma levels. On the other hand, inherited type II antithrombin deficiency is a qualitative disorder that is characterized by defects in the antithrombin molecule. Acquired antithrombin deficiencies are more common than hereditary deficiencies and are associated with various clinical conditions due to reduced synthesis, increased loss, or enhanced consumption. The purpose of this review was to provide an update on the structure, functions, clinical implications, and methods of detection of antithrombin.
(Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.)
References: Lipe B, Ornstein DL. Deficiencies of natural anticoagulants, protein C, protein S, and antithrombin. Circulation 2011; 124:e365–e368.
Dahlbäck B. Blood coagulation. Lancet 2000; 355:1627–1632.
Osunkalu V, Kanu O, Ngwuli F. Antithrombin III: plasma activity and reference range among Nigerian blood donors. Niger Postgrad Med J 2015; 22:209–212.
Patnaik MM, Moll S. Inherited antithrombin deficiency: a review. Haemophilia 2008; 14:1229–1239.
Cooper PC, Coath F, Daly ME, Makris M. The phenotypic and genetic assessment of antithrombin deficiency. Int J Lab Hematol 2011; 33:227–237.
Langdown J, Belzar KJ, Savory WJ, Baglin TP, Huntington JA. The critical role of hinge-region expulsion in the induced-fit heparin binding mechanism of antithrombin. J Mol Biol 2009; 386:1278–1289.
Stein PE, Leslie AGW, Finch JT, Turnell WG, McLaughlin PJ, Carrell RW. Crystal structure of ovalbumin as a model for the reactive centre of serpins. Nature 1990; 347:99–102.
Miyawaki Y, Suzuki A, Fujita J, Maki A, Okuyama E, Murata M, et al. Thrombosis from a prothrombin mutation conveying antithrombin resistance. N Engl J Med 2012; 366:2390–2396.
Mannucci PM, Franchini M. Classic thrombophilic gene variants. Thromb Haemost 2015; 114:885–889.
Caspers M, Pavlova A, Driesen J, Harbrecht U, Klamroth R, Kadar J, et al. Deficiencies of antithrombin, protein C and protein S - practical experience in genetic analysis of a large patient cohort. Thromb Haemost 2012; 108:247–257.
Heit C, Jackson BC, McAndrews M, Wright MW, Thompson DC, Silverman GA, et al. Update of the human and mouse SERPIN gene superfamily. Hum Genomics 2013; 7:22.
Steiner M, Steiner B, Rolfs A, Wangnick M, Burstein C, Freund M, Schuff-Werner P. Antithrombin gene mutation 5356-5364∗ delCTT with type I deficiency and early-onset thrombophilia and a brief review of the antithrombin (-helix D molecular pathology. Ann Hematol 2005; 84:56–58.
Yoo JH, Maeng HY, Kim HJ, Lee KA, Choi JR, Song J. Case report: a heparin binding site Arg79Cys missense mutation in the SERPINC1 gene in a Korean patient with hereditary antithrombin deficiency. Ann Clin Lab Sci 2011; 41:89–92.
Mulder R, Meijer K, Lukens MV. Genetic testing of hereditary antithrombin deficiency in a large US pedigree using saliva samples. Int J Lab Hematol 2021; 43:e101–e103.
Luxembourg B, Delev D, Geisen C, Spannagl M, Krause M, Miesbach W, et al. Molecular basis of antithrombin deficiency. Thromb Haemost 2011; 105:635–646.
Fischer R, Sachs UJ, Heidinger KS, Eisenburger D, Kemkes-Matthes B. Prevalence of hereditary antithrombin mutations is higher than estimated in patients with thrombotic events. Blood Coagul Fibrinolysis 2013; 24:444–448.
Zheng H, Ma HP, Xu WF, Zhang YQ, Wu JJ, Wang J. Identification of a new SERPINC1 mutation in a Kazak family that alters the heparin binding capacity of antithrombin. Thromb Res 2014; 134:1344–1349.
Corral J, de la Morena-Barrio ME, Vicente V. The genetics of antithrombin. Thromb Res 2018; 169:23–29.
Jin Y, Yegneswaran S, Gu JM, Gritzan U, Schönfeld DL, Paz P, et al. Identification and function probing of an antithrombin IIIβ conformation-specific antibody. J Thromb Haemost 2016; 14:356–365.
Andersen Ø, Flengsrud R, Norberg K, Salte R. Salmon antithrombin has only three carbohydrate side chains, and shows functional similarities to human β-antithrombin. Eur J Biochem 2000; 267:1651–1657.
Amiral J, Seghatchian J. Revisiting antithrombin in health and disease, congenital deficiencies and genetic variants, and laboratory studies on α and β forms. Transfus Apher Sci 2018; 57:291–297.
Karlaftis V, Sritharan G, Attard C, Corral J, Monagle P, Ignjatovic V. Beta (β)-antithrombin activity in children and adults: Implications for heparin therapy in infants and children. J Thromb Haemost 2014; 12:1141–1144.
Imoru M. Protein C and antithrombin III activities in healthy Nigerian women. Inter J Hematol Res 2015; 1:20–23.
Liumbruno GM, Franchini M, Lanzoni M, Candura F, Vaglio S, Profili S, et al. Clinical use and the Italian demand for antithrombin. Blood Transfus 2013; 11:s86–s93.
Gray E, Hogwood J, Mulloy B. The anticoagulant and antithrombotic mechanisms of heparin. Handb Exp Pharmacol 2012; 207:43–61.
Johnson DJD, Huntington JA. Crystal structure of antithrombin in a heparin-bound intermediate state. Biochemistry 2003; 42:8712–8719.
Foy P, Moll S. Thrombophilia: 2009 update. Curr Treat Options Cardiovasc Med 2009; 11:114–118.
Levy JH, Sniecinski RM, Welsby IJ, Levi M. Antithrombin: anti-inflammatory properties and clinical applications. Thromb Haemost 2016; 115:712–728.
Gierer P, Laue F, Hoffmann JN, Rotter R, Mittlmeier T, Gradl G, Vollmar B. Antithrombin reduces inflammation and microcirculatory perfusion failure in closed soft-tissue injury and endotoxemia. Crit Care Med 2013; 41:867–873.
Azhar A, Singh P, Rashid Q, Naseem A, Sazzad Khan M, Aman Jairajpuri M. Antiangiogenic function of antithrombin is dependent on its conformational variation: implication for other Serpins. Protein Pept Lett 2013; 20:403–411.
O’Reilly MS, Pirie-Shepherd S, Lane WS, Folkman J. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science (80-) 1999; 285:1926–1928.
Zhang W, Chuang YJ, Jin T, Swanson R, Xiong Y, Leung L, Olson ST. Antiangiogenic antithrombin induces global changes in the gene expression profile of endothelial cells. Cancer Res 2006; 66:5047–5055.
Luengo-Gil G, Calvo MI, Martín-Villar E, Águila S, Bohdan N, Antón AI, et al. Antithrombin controls tumor migration, invasion and angiogenesis by inhibition of enteropeptidase. Sci Rep 2016; 6:27544.
Whitney JB, Asmal M, Geiben-Lynn R. Serpin induced antiviral activity of prostaglandin synthetase-2 against HIV-1 replication. PLoS One 2011; 6:e18589.
Asmal M, Seaman M, Lin W, Chung RT, Letvin NL, Geiben-Lynn R. Inhibition of HCV by the serpin antithrombin III. Virol J 2012; 9:266.
Smee DF, Hurst BL, Day CW, Geiben-Lynn R. Influenza virus H1N1 inhibition by serine protease inhibitor (serpin) antithrombin III. Int trends Immun 2014; 2:83–86.
Khor B, Van Cott EM. Laboratory tests for antithrombin deficiency. Am J Hematol 2010; 85:947–950.
James AH, Konkle BA, Bauer KA. Prevention and treatment of venous thromboembolism in pregnancy in patients with hereditary antithrombin deficiency. Int J Womens Health 2013; 3:233–241.
Norlelawati AT, Rusmawati I, Nur Nadia O, Naznin M, Rizqan Aizzani R, Noraziana AW. Inherited antithrombin deficiency in a malay-malaysian family: a missense mutation at nucleotide g.13267C>A aka antithrombin budapest 5 (p.pro439thr) of the SERPINC 1 gene. Med J Malaysia 2014; 69:27–30.
Ishiguro K, Kojima T, Kadomatsu K, Nakayama Y, Takagi A, Suzuki M, et al. Complete antithrombin deficiency in mice results in embryonic lethality. J Clin Invest United States 2000; 106:873–878.
Găman AM, Găman GD. Deficiency of antithrombin III (AT III) - case report and review of the literature. Curr Heal Sci J 2014; 40:141–143.
Kujovich J, Merrill PA. Antiphospholipid antibodies and antithrombin deficiency: double trouble for pregnancy. Am J Hematol 2011; 86:1028–1031.
Deng H, Shen W, Gu Y, Ma X, Zhang J, Zhang L. Three case reports of inherited antithrombin deficiency in China: Double novel missense mutations, a nonsense mutation and a frameshift mutation. J Thromb Thrombolysis 2012; 34:244–250.
Sarper N, Orlando C, Demirsoy U, Gelen SA, Jochmans K. Homozygous antithrombin deficiency in adolescents presenting with lower extremity thrombosis and renal complications: two case reports from Turkey. J Pediatr Hematol Oncol 2014; 36:e190–e192.
Mackie I, Cooper P, Lawrie A, Kitchen S, Gray E, Laffan M. British Committee for Standards in Haematology. Guidelines on the laboratory aspects of assays used in haemostasis and thrombosis. Int J Lab Hematol 2013; 35:1–13.
Blajchman M, Austin R, Fernandez-Rachubinski F, Sheffield W. Molecular basis of inherited human antithrombin deficiency. Blood 1992; 80:2159–2171.
Jeffers A, Owens S, Koenig K, Quaid B, Pendurthi UR, Rao VM, et al. Thrombin down-regulates tissue factor pathway inhibitor expression in a PI3K/nuclear factor-kB-dependent manner in human pleural mesothelial cells. Am J Respir Cell Mol Biol 2015; 52:674–682.
Orlando C, Heylen O, Lissens W, Jochmans K. Antithrombin heparin binding site deficiency: a challenging diagnosis of a not so benign thrombophilia. Thromb Res 2015; 135:1179–1185.
Liumbruno GM, Bennardello F, Lattanzio A, Piccoli P, Rossetti G. Italian Society of Transfusion Medicine and Immunohaematology (SIMTI) Working Party. Recommendations for the use of antithrombin concentrates and prothrombin complex concentrates. Blood Transfus 2009; 7:325–334.
Muciño-Bermejo J, Carrillo-Esper R, Uribe M, Méndez-Sánchez N. Coagulation abnormalities in the cirrhotic patient. Ann Hepatol 2013; 12:713–724.
Bhalli A, Mohsin S, Aslam M, Saeed T, Hussain S, Bashir N. Antithrombin iii as marker of fibrosis in chronic hepatitis c. Biomedica 2015; 31:228–231.
Lu Z, Wang F, Liang M. SerpinC1/antithrombin III in kidney-related diseases. Clin Sci 2017; 131:823–831.
Muller G. Acquired antithrombin III deficiency. Z Gesamte Inn Med 1992; 47:74–77.
Ali N, Ayyub M, Khan SA. High prevalence of protein C, protein S, antithrombin deficiency, and factor V Leiden mutation as a cause of hereditary thrombophilia in patients of venous thromboembolism and cerebrovascular accident. Pakistan J Med Sci 2014; 30:1323–1326.
Khalid S, Sajid R, Adil SN, Khurshid M. Frequency of hereditary thrombophilia: an AKUH experience. J Pak Med Assoc 2004; 54:427–429.
Jackson BR, Holmes K, Phansalkar A, Rodgers GM. Testing for hereditary thrombophilia: a retrospective analysis of testing referred to a national laboratory. BMC Clin Pathol 2008; 8:3.
Kreidy R, Irani-Hakime N. Is thrombophilia a major risk factor for deep vein thrombosis of the lower extremities among Lebanese patients? Vasc Health Risk Manag 2009; 5:627–633.
Ornaghi S, Barnhart KT, Frieling J, Streisand J, Paidas MJ. Clinical syndromes associated with acquired antithrombin deficiency via microvascular leakage and the related risk of thrombosis. Thromb Res 2014; 133:972–984.
Tait RC, Walker ID, Perry DJ, Islam SIAM, Daly ME, McCall F, et al. Prevalence of antithrombin deficiency in the healthy population. Br J Haematol 1994; 87:106–112.
Johnson NV, Khor B, Van Cott EM. Advances in laboratory testing for thrombophilia. Am J Hematol 2012; 87:S108–S112.
Demers C, Henderson P, Blajchman MA, Wells MJ, Mitchell L, Johnston M, et al. An antithrombin III assay based on factor Xa inhibition provides a more reliable test to identify congenital antithrombin III deficiency than an assay based on thrombin inhibition. Thromb Haemost 1993; 69:231–235.
Baker P, Platton S, Gibson C, Gray E, Jennings I, Murphy P, Laffan M. British Society for Haematology, Haemostasis and Thrombosis Task Force. Guidelines on the laboratory aspects of assays used in haemostasis and thrombosis. Br J Haematol 2020; 191:347–362.
Rossi E, Chiusolo P, Za T, Marietti S, Ciminello A, Leone G, De Stefano V. Report of a novel kindred with antithrombin heparin-binding site variant (47 Arg to His): demand for an automated progressive antithrombin assay to detect molecular variants with low thrombotic risk. Thrombo Haemost 2007; 98:695–697.
Kottke-Marchant K, Duncan A. Antithrombin deficiency: issues in laboratory diagnosis. Arch Pathol Lab Med 2002; 126:1326–1336.
Zeng W, Tang L, Jian X-R, Li Y-Q, Guo T, Wang Q-Y, et al. Genetic analysis should be included in clinical practice when screening for antithrombin deficiency. Thromb Haemost 2015; 113:262–271.
المشرفين على المادة: 0 (Antithrombins)
9000-94-6 (Antithrombin III)
0 (Anticoagulants)
9005-49-6 (Heparin)
تواريخ الأحداث: Date Created: 20240105 Date Completed: 20240205 Latest Revision: 20240308
رمز التحديث: 20240308
DOI: 10.1097/MBC.0000000000001271
PMID: 38179715
قاعدة البيانات: MEDLINE
الوصف
تدمد:1473-5733
DOI:10.1097/MBC.0000000000001271